Aegera has developed extremely potent small molecule IAP inhibitors by targeting functional domains on the individual IAP proteins; These compounds possess good pharmacokinetic/pharmacodynamic properties and stability and demonstrate potent anticancer activity, alone and in combination with current cancer therapies and death receptor agonists. In December 2007, Aegera and Human Genome Sciences, Inc. (Nasdaq:HGSI) completed a licensing and collaboration agreement providing HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize AEG40826 (HGS1029) and other small-molecule IAP inhibitors in oncology. Aegera has retained global rights for the use of its small molecules IAP inhibitors in all indications outside oncology. AEG40826/HGS1029 is currently progressing in Phase 1 studies.

This schematic illustrates how our small molecule IAP inhibitors function by inhibiting several IAP family members including XIAP, cIAP-1 and cIAP-2, proteins which play key roles in the modulation of both the mitochondrial and death receptor-mediated apoptosis pathways.

	November 23, 2009 Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS 1029 in Advanced Lymphoid Tumors
	June 10, 2008 Aegera Therapeutics Collaboration with Human Genome Sciences leads to the Initiation of a Phase 1 clinical trial with lead IAP Inhibitor Hgs1029 and receipt of first milestone payment
	December 20, 2007 HGS and Aegera announce licensing and collaboration agreement on Novel Anti-Cancer drugs